Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (02) : 116-122     DOI: 10.3971/j.issn.1000-8578.2022.21.0553
|
Effect of Lymph Node Metastasis on Prognosis of Small Cell Lung Cancer with M1a Disease: A Study Based on SEER database
YANG Hao, MEI Tonghua
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Download: PDF(3759 KB)   ( 45 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To investigate the impact of lymph node metastasis on the survival of SCLC patients with M1a disease. Methods We retrospectively analyzed the medical records of 7027 SCLC patients with M1a disease from 2004 to 2015 in SEER database. The Kaplan-Meier method and log-rank test were used to estimate the OS in all N stage subgroups. Cox proportional hazard model was used to assess whether N stage was an independent risk factor for prognosis. Results The median OS of all patients was 7 months. Among all M1a patients, the patients without lymph node involvement (N0) had the best OS, followed by N1 stage patients; N2 and N3 stage patients had the worst OS (P<0.001). Similarly, this trend was observed when M1a disease was subdivided into contralateral pulmonary nodules, malignant pleural effusion and malignant pericardial effusion. Multivariate analysis showed that lymph node metastasis was an independent prognostic factor for SCLC patients with M1a disease, and this result was also noticed in all subgroups of M1a disease. Conclusion Lymph node metastasis may affect the survival of SCLC patients with M1a disease, adding prognostic information. And it is recommended to further improve the N descriptor in the next version of TNM staging system.
Keywords Small cell lung cancer      N stage      M1a stage      SEER database      Prognosis     
ZTFLH:  R734.2  
Issue Date: 17 February 2022
 Cite this article:   
YANG Hao,MEI Tonghua. Effect of Lymph Node Metastasis on Prognosis of Small Cell Lung Cancer with M1a Disease: A Study Based on SEER database[J]. Cancer Research on Prevention and Treatment, 2022, 49(02): 116-122.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.0553
http://www.zlfzyj.com/EN/Y2022/V49/I02/116
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
YANG Hao
MEI Tonghua
[1] Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung
cancer[J]. Nat Rev Dis Primers, 2021, 7(1): 3.
[2] Hiddinga BI, Raskin J, Janssens A, et al. Recent developments in
the treatment of small cell lung cancer[J]. Eur Respir Rev, 2021,
30(161): 210079.
[3] Poirier JT, George J, Owonikoko TK, et al. New Approaches to
SCLC Therapy: From the Laboratory to the Clinic[J]. J Thorac
Oncol, 2020, 15(4): 520-540.
[4] Nicholson AG, Chansky K, Crowley J, et al. The International
Association for the Study of Lung Cancer Lung Cancer Staging
Project: Proposals for the Revision of the Clinical and Pathologic
Staging of Small Cell Lung Cancer in the Forthcoming Eighth
Edition of the TNM Classification for Lung Cancer[J]. J Thorac
Oncol, 2016, 11(3): 300-311.
[5] Lin X, Xiao Z, Hu Y, et al. Combining 18F-FDG PET/CT and
Serum Lactate Dehydrogenase for Prognostic Evaluation of Small Cell Lung Cancer[J]. Front Pharmacol, 2020,11: 592768.
[6] Dingemans AC, Früh M, Ardizzoni A, et al. Small-cell lung
cancer: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up[J]. Ann Oncol, 2021, 32(7): 839-853.
[7] 张文珏, 朱慧, 周宗玫, 等. TNM分期在局限期小细胞肺癌预
后评估中的价值[J]. 中华肿瘤杂志, 2015, 37(12): 917-922.
[Zhang WJ, Zhu H, Zhou ZM, et al. Prognostic value of AJCC
TNM Staging 7th edition in limited-stage small cell lung cancer:
validation in 437 patients[J]. Zhonghua Zhong Liu Za Zhi, 2015,
37(12): 917-922.]
[8] Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung
Cancer Staging Project: Proposals for Revision of the TNM Stage
Groupings in the Forthcoming (Eighth) Edition of the TNM
Classification for Lung Cancer[J]. J Thorac Oncol, 2016, 11(1):
39-51.
[9] Vallières E, Shepherd FA, Crowley J, et al. The IASLC Lung
Cancer Staging Project: proposals regarding the relevance of
TNM in the pathologic staging of small cell lung cancer in the
forthcoming (seventh) edition of the TNM classification for lung
cancer[J]. J Thorac Oncol, 2009, 4(9): 1049-1059.
[10] Dai C, Ren Y, Xie D, et al. Does Lymph Node Metastasis Have
a Negative Prognostic Impact in Patients with NSCLC and M1a
Disease?[J]. J Thorac Oncol, 2016, 11(10): 1745-1754.
[11] Rami-Porta R, Asamura H, Travis WD, et al. Lung cancer - major
changes in the American Joint Committee on Cancer eighth
edition cancer staging manual[J]. CA Cancer J Clin, 2017, 67(2):
138-155.
[12] Asamura H, Chansky K, Crowley J, et al. The International
Association for the Study of Lung Cancer Lung Cancer Staging
Project: Proposals for the Revision of the N Descriptors in the
Forthcoming 8th Edition of the TNM Classification for Lung
Cancer[J]. J Thorac Oncol, 2015, 10(12): 1675-1684.
[13] Iida T, Shiba M, Yoshino I, et al. Surgical Intervention for Non-
Small-Cell Lung Cancer Patients with Pleural Carcinomatosis:
Results From the Japanese Lung Cancer Registry in 2004[J]. J
Thorac Oncol, 2015, 10(7): 1076-1082.
[14] Ryu JS, Lim JH, Lee JM, et al. Minimal Pleural Effusion in Small
Cell Lung Cancer: Proportion, Mechanisms, and Prognostic
Effect[J]. Radiology, 2016, 278(2): 593-600.
[15] Kato R, Hayashi H, Chiba Y, et al. Prognostic Impact of Minimal
Pericardial Effusion in Patients With Advanced Non-small-cell
Lung Cancer[J]. Clin Lung Cancer, 2017, 18(6): e449-e455.
[16] Morris ZS, Cannon DM, Morris BA, et al. Impact of a
Contralateral Tumor Nodule on Survival in Non-Small-Cell Lung
Cancer[J]. J Thorac Oncol, 2015, 10(11): 1608-1615.
[17] Ignatius Ou SH, Zell JA. The applicability of the proposed
IASLC staging revisions to small cell lung cancer (SCLC) with
comparison to the current UICC 6th TNM Edition[J]. J Thorac
Oncol, 2009, 4(3): 300-310.
[18] Girard N, Ostrovnaya I, Lau C, et al. Genomic and mutational
profiling to assess clonal relationships between multiple non-small
cell lung cancers[J]. Clin Cancer Res, 2009, 15(16): 5184-5190.
[19] 王继凡, 张特, 丁翰林, 等. 同时性多原发肺癌与肺内转移鉴别
方法研究进展[J]. 中国肺癌杂志, 2021, 24(5): 365-371. [Wang
JF, Zhang T, Ding HL, et al. Research Progress in Distinguishing
Methods of Simultaneous Multiple Primary Lung Cancer and
Intrapulmonary Metastasis[J]. Zhongguo Fei Ai Za Zhi, 2021,
24(5): 365-371.]
[20] Zou J, Guo S, Xiong MT, et al. Ageing as key factor for distant
metastasis patterns and prognosis in patients with extensive-stage
Small Cell Lung Cancer[J]. J Cancer, 2021, 12(6): 1575-1582.
[21] Huang LL, Hu XS, Wang Y, et al. Survival and pretreatment
prognostic factors for extensive-stage small cell lung cancer: A
comprehensive analysis of 358 patients[J]. Thorac Cancer, 2021,
12(13): 1943-1951.
[22] Lim JH, Ryu JS, Kim JH, et al. Gender as an independent
prognostic factor in small-cell lung cancer: Inha Lung Cancer
Cohort study using propensity score matching[J]. PLoS One,
2018, 13(12): e0208492.
[23] Zhou K, Shi H, Chen R, et al. Association of Race, Socioeconomic
Factors, and Treatment Characteristics With Overall Survival in
Patients With Limited-Stage Small Cell Lung Cancer[J]. JAMA
Netw Open, 2021, 4(1): e2032276.
[24] Shan Q, Shi J, Wang X, et al. A new nomogram and risk
classification system for predicting survival in small cell
lung cancer patients diagnosed with brain metastasis: a large
population-based study[J]. BMC Cancer, 2021, 21(1): 640.
[25] Daly ME, Ismaila N, Decker RH, et al. Radiation Therapy for
Small-Cell Lung Cancer: ASCO Guideline Endorsement of an
ASTRO Guideline[J]. J Clin Oncol, 2021, 39(8): 931-939.
[26] Sheikh S, Dey A, Datta S, et al. Role of radiation in extensive
stage small cell lung cancer: a National Cancer Database registry
analysis[J]. Future Oncol, 2021, 17(21): 2713-2724.
[27] Lee JS, Kim S, Sung SY, et al. Treatment Outcomes of 9,994
Patients With Extensive-Disease Small-Cell Lung Cancer From a
Retrospective Nationwide Population-Based Cohort in the Korean
HIRA Database[J]. Front Oncol, 2021, 11: 546672.
[28] Noronha V, Ravind R, Patil VM, et al. The role of chemotherapy
in patients with small cell lung cancer and poor performance
status[J]. Acta Oncol, 2020, 59(12): 1520-1527.
Related articles from Frontiers Journals
[1] TIAN Zhen, ZHU Neng, LI Zilin, CHEN Yongzhong, LI Hong, ZHANG Xinhua. Effect of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia in Locally Advanced Non-small Cell Lung Cancer Patients at Nutritional Risk[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 904-907.
[2] LI Jinzhou, WANG Wenjie, YAO Yalong, MU Yanxi, CHEN Kang, SHEN Yimin, WANG Zhou, HUANG Zeping, CHEN Xiao. Development and Validation of Prognostic Nomogram Based on Negative Lymph Node Count for Patients with Gastric Signet Ring Cell Carcinoma#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 923-930.
[3] HUANG Zhenghua, ZHOU Jian, LI Yufu, LIU Yanyan, ZHOU Keshu, SONG Yongping. Clinical Efficacy and Prognostic Factors of Autologous Hematopoietic Stem Cell Transplantation for Hodgkin’s Lymphoma in 38 Cases[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 952-955.
[4] XU XiaoFei, LI Yang, CHEN Lingyun, DAI Heyang, XUE Jiaojiao, LI Qingxia, . Research Progress of PNI and CONUT in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 961-964.
[5] JIA Lijuan, ZHANG Yunqiang, ZHANG Baihong, YUE Hongyun. Expression and Clinical Significance of m6A Methylatransferase ZC3H13 in Gastric Cancer Tissues and Serum[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 792-798.
[6] SUI Daxing, WANG Xueying, ZHANG Jiaxin. A New N-staging System for Predicting Postoperative Survival of M0 Stage Inflammatory Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 799-805.
[7] LI Jinzhou, HUANG Zeping, MU Yanxi, YAO Yalong, WANG Wenjie, LIU Haipeng, LIU Jie, WANG Zhou, CHEN Xiao. Prognostic Value of Negative Lymph Nodes Count in Solid Tumors[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 843-849.
[8] CHEN Yarui, WANG Jiangtao, GUAN Quanlin, JI Wei, JIAO Fuzhi. Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 855-860.
[9] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[10] XIA Lili, ZHU Xinyi, ZHANG Xiwei, LI Zhengjiang, LIU Shaoyan, LU Haizhen, AN Changming. Predictive Value of Depth of Invasion of Tongue Squamous Cell Carcinoma for Cervical Lymph Node Metastasis and Prognosis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 675-681.
[11] ZHAN Jianghua, WANG Zhiru, . Progress and Comment on Surgical Treatment of Hepatoblastoma in Children[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 541-545.
[12] . Expression of MAD2L1 in Lung Adenocarcinoma and Its Effect on Immune Microenvironment[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 586-592.
[13] WANG Jue, JIN Zongrui, WANG Wei, YI Qilin, WANG Jilong, ZHU Hai, XU Banghao, GUO Ya, WEN Zhang. Prognostic Role of Immune-related Genes in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 599-605.
[14] LI Menghan, XIAO Qiong, GAO Peng, FU Yu, SUN Chenrui, SONG Yongxi. LncRNA Prognostic Risk Scoring Model for Gastrointestinal Tumors Based on TCGA Database[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 606-611.
[15] XU Shasha, HAN Xingmin. Research Advances on Application of 18F-FDG PET/CT in Clinical Diagnosis and Treatment of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 384-389.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed